Subscribe Sign in

Health

Shares surge as ASX biotech charts road to redemption

1 min read Rewritten in plain language

Healthcare Shares

Changed after publishing · 1 edit
  • the report was edited: 208 words added, 4 removed.

Outlets edit stories after they go out, usually without saying so. We keep what we saw the first time.

Show what we removed Rules applied: A1 A4 C2 D2 D3×2 E3×2 F2 all 30 rules
  • Shares in Echo IQ Ltd (ASX: EIQ) jumped more than 10% after the company said it believed there was a "clear path" to getting regulatory approval in the US for its EchoSolv HF technology.
  • The Company's assessment has not identified concerns relating to the underlying technology or core functionality of the EchoSolv HF device, and Echo IQ remains confident that clearance remains achievable under the 510 route.
  • The company's shares were 10.7% higher at 57 cents on Thursday.

3 sentences from our version of the report, chosen to cover it. Nothing here is written; every line is in the article below. How

Headline check

There is nothing in this headline a machine can check against the report: no figure, no name and no quotation.

Nothing was measured here, so nothing is claimed. How this is checked

Shares in Echo IQ Ltd (ASX: EIQ) jumped more than 10% after the company said it believed there was a "clear path" to getting regulatory approval in the US for its EchoSolv HF technology.

Echo IQ shares fell almost 50% last week when the company said that the US Food & Drug Administration had issued a Not Substantially Equivalent determination for the company's application for the approval of clinical use of EchoSolv HF.

The company said it "believes there is a path forward to getting FDA clearance for EchoSolv HF and it's progressing this as a priority''."

The Company's assessment has not identified concerns relating to the underlying technology or core functionality of the EchoSolv HF device, and Echo IQ remains confident that clearance remains achievable under the 510 route. Echo IQ has identified multiple potential pathways to progress EchoSolv HF towards FDA clearance, including an administrative appeal of the NSE determination, seeking review through the FDA Ombudsman, or submitting a new 510 application.

The company's shares were 10.7% higher at 57 cents on Thursday.

Shortened to 1 minute of reading, this version reads 6.2 on the Niral Score.

You are reading our version, not theirs. This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with verdicts and loaded words taken out. Plain description stays, and so do adjectives that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations are theirs — quotations are never edited — and the indicators beside it measure this version. Hover or tap Adjectives to see every one left in the text.

How this outlet filed it, and how we rewrote it

No other newsroom we read has filed on this event, so there is nothing to compare it with yet.

Outlet Niral ScoreAdjectivesSourcingSentimentHappiness
The Motley Fool Australiaas they published this story 8.6 3 58 -0.1 47.8
Mundane Readneutralized from The Motley Fool Australia 6.9 2 58 -0.1 47.8

Sign in to react.

Comments

Nothing here yet.

Sign in to comment.

Questions

Readers can ask a question about this story here. Questions and answers are for subscribers. Sign in to read them.

Comments are read before they appear where anything in them needs a person to look. Nothing posted here is ever deleted; a comment taken down keeps its text and the reason, so the decision can be looked at again. How this works